RYSE Asset Management LLP (RYSE), an FCA authorised and regulated investment manager, has formed a partnership in exclusivity with DigitalHealth.London and MedCity.
We identify, support, and invest in early stage digital health companies, to commercialise and scale within the NHS and other healthcare delivery systems. To maximise the probability of success, RYSE provides companies and investors with a unique offering:
DEAL FLOW
TECHNOLOGICAL VALIDATION
NHS ACCESS
DUE DILIGENCE
RYSE ECOSYSTEM
DISTRIBUTION
300-500 companies are reviewed over 12 months. Most are attracted to RYSE via the DH.L programme, however, further deals are generated via our network.
Science and technologies are validated by an expert panel of reviewers (NHS, DH.L, and MedCity).
The companies benefit from unparalleled access to NHS executives, decision makers within NHS organisations, and central NHS policy makers.
RYSE has a detailed and comprehensive commercial due diligence process that is tailored to the requirements of early-stage digital health companies.
Seasoned investors, mentors, academics, and industry experts all assist our companies. This is through one-to-one meetings and exclusive targeted events.
The process provides access to alternative distribution channels and potential exit strategies i.e. global health insurance companies, private health providers, and positioning of our NHS vetted companies for long term distribution into the NHS.
